Kornimate/medical-research-clean huggingface dataset:
analysis of risk factors of postoperative pulmonary infection in patients with esophageal cancer

Conditions: Esophageal Neoplasms; Pneumonia

Summary: the goal of this observational study is to learn about in describe participant population. the main questions it aims to answer are: * what are the risk factors of postoperative pulmonary infection in patients with esophageal cancer？ * whether we could establish a clinical prediction model to provide basis for early clinical intervention or not? participants will describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items. if there is a comparison group: researchers will compare insert groups to see if insert effects.

data were collected from the electronic medical records of xijing hospital. each record is entered by two team members working simultaneously to ensure data accuracy.

Eligibility criteria:
inclusion criteria: * diagnosis of esophageal cancer; * radical resection of tumor for the first time; * no distant metastasis was observed in preoperative examination exclusion criteria: * patients with preoperative pulmonary infection or symptoms of pulmonary infection; * patients with tracheal intubation assisted ventilation before surgery; * patients with preoperative lung imaging changes or abnormal white blood cells in blood routine; * patients undergoing emergency surgery; * patients with other cancers; * patients with incomplete clinical data.
point of care testing to improve monitoring of lvad patients

Conditions: Anticoagulation and Thrombosis Point of Care Test (AT-POCT)

Summary: the purpose of this study is to develop and validate the accuracy of a low-cost "point-of-care" test (poct) that allows monitoring of markers for anticoagulation and thrombosis (local coagulation or clotting of the blood), to be used by patients with advanced heart failure (ahf) on left ventricular assist device (lvad) support. the investigators central hypothesis is that the fully-printed at-poct utilizing low-cost (printed) cassettes and detector will produce an inexpensive and convenient option for daily self-monitoring of pt/inr and ldh over existing methods.


Eligibility criteria:
inclusion criteria: * 18 to 80 years of age * subject has signed informed consent form (icf) * for lvad patient cohort, they are on lvad support from 2 weeks to 10 years. exclusion criteria: * patients with dementia, altered mental status, any psychiatric condition or mental disability that would prohibit the understanding or rendering of informed consent are not eligible * prisoners
low-dose versus a high-dose sublingual buprenorphine induction

Conditions: Opioid Use Disorder

Summary: this study proposes to compare a low-dose versus a high-dose buprenorphine induction scheme in 40 fentanyl using people with opioid use disorder (oud). study participants will be randomized to either the low-dose (n=20) or high dose (n=20) group and dispensed medication daily for one week.

this study proposes to compare a low-dose versus a high-dose buprenorphine induction scheme in 40 fentanyl using people with opioid use disorder (oud). study participants will be randomized to either the low-dose (n=20) or high dose (n=20) group and dispensed medication daily for one week. thereafter, they will be treated according to the matclinics usual schedule of clinic visits. the number and timing of visits may vary according to whether the participant is still using illicit opioids. follow-up visits for the study will be at one and three months.the primary objective is to determine whether patients randomly assigned to low versus high dose induction regimens are more likely to complete the 7-day induction period. secondary outcomes are the number of patients who develop precipitated withdrawal or other adverse events, experience subjective opioid withdrawal symptoms, use adjunctive medications (hydroxyzine, loperamide, dicyclomine, clonidine, ibuprofen, methocarbamol, trazodone, ondansetron) provided by the clinic, recommendation of the medication induction scheme to other patients, and treatment retention at 1- and 3- months post induction.

Eligibility criteria:
inclusion criteria: * adult male or female (≥ 18 years of age) persons with a dsm-5 diagnosis of oud; * must have a fentanyl positive urine test; * able to come to the clinic every day for the first week of treatment. exclusion criteria: * no exclusionary medical history or mental health issues as determined by the admitting provider; e.g., patients with untreated or unstable serious mental illness, including psychotic disorders; * alcohol withdrawal requiring pharmacological management; * urine positive for buprenorphine, benzodiazepines, or methadone; 4. enrolled in a methadone treatment program in the past 14 days; 5. inability to pass a study enrollment quiz.
safety and efficacy of an anticancer medication combined with immune cells in subjects with solid tumors

Conditions: Advanced Solid Tumors

Summary: this is an open-label study to evaluate the safety and efficacy of an anticancer medication (a01) with immune cells (ic01) in subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. signed informed consent form must be obtained prior to any research procedures; 2. age: 18 years to 70 years; 3. the patient's biological parent or child whose age ≥18 years voluntarily donates peripheral blood (100-200 ml) for the treatment, and who signs the informed consent form independently; 4. histologically confirmed diagnosis of solid tumors; 5. patients who have received at least one standard treatment (surgery, chemotherapy, radiotherapy, or targeted therapy) or refuse to receive standard treatments; 6. kps \> 60 points; 7. expected survival \> 6 months; 8. adequate organ function defined as: anc≥1.0×10\^9/l, plt≥50×10\^9/l, alb≥25g/l; 9. if a subject is a female of childbearing potential, she must have a negative urine pregnancy test result. exclusion criteria: 1. patients who received chemotherapy, large-field radiotherapy or participated in other studies of anti-tumor therapy within 2 weeks before enrollment; 2. patients who have not recovered from adverse reactions related to above-mentioned procedures; 3. patients with two types of primary solid tumors; 4. patients with brain metastases or bone metastases; 5. patients with poorly controlled hypertension (systolic blood pressure \> 160 mmhg and/or diastolic blood pressure \> 90 mmhg), or cardiovascular and cerebrovascular diseases with clinical significance, such as cerebrovascular accident (within 6 months before signing informed consent), myocardial infarction (within 6 months before signing informed consent), unstable angina, congestive heart failure (new york heart association classⅱ or above), or severe arrhythmia which can't be controlled with drugs or have potential impact on the treatment; 6. patients with other serious organic diseases or mental disorders; 7. patients with systemic or active infection; 8. patients with positive hiv test result; 9. patients who have received an organ transplant; 10. patients who are breastfeeding or pregnant.
a study to investigate hcv response rates in real world patients: heartland study

Conditions: Chronic Hepatitis C

Summary: this is a phase iv, open label, single center study of obv/ptv/r + dsv +/- rbv for 12 or 24 weeks for the treatment of chronic hcv-1 infection in a real world urban clinical setting.

this is a phase iv, open label, single center study of obv/ptv/r + dsv +/- rbv for 12 or 24 weeks for the treatment of chronic hcv-1 infection in a real world urban clinical setting. the study will enroll chronically infected gt 1 patients who are treatment naïve or who have failed a regimen including pegifn/rbv +/- telaprevir, boceprevir, or simeprevir. in addition, up to 20 chronically infected gt1 patients who have traditionally been excluded from clinical trials due to mild to moderate renal insufficiency, irrespective of other co-morbid conditions including poorly controlled diabetes mellitus, high bmi, hiv infection will be enrolled.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients must have chronic gt 1 hcv infection (gt1a, gt1b or gt1a/1b) * patient and partner(s) must agree to use acceptable methods of contraception * patient must be able to read and understand english and/or spanish * written informed consent exclusion criteria: * currently taking or planning on taking any prohibited medications (see us pi) * evidence of decompensated liver disease (child-pugh b or c) including the presence of clinical ascites, bleeding varices, or hepatic encephalopathy * abnormal lab values, including: * hemoglobin (hgb) \<8 g/dl * platelets \<25,000 cells/mm3 * absolute neutrophil count (anc)\<500 cells/mm3 * bilirubin \>3 * inr\>2.3 alt/ast \> 10 x uln * serum albumin \<2.8 * gfr \<30 ml * alcohol use: \>3 drinks per day consistently * uncontrolled hiv or hbv coinfection
study of tu7710 in warfarin anti-coagulated healthy male subjects

Conditions: Hemophilia a; Hemophilia B; Blood Coagulation Disorders

Summary: this is a phase 1a, double-blind, randomized, placebo- controlled, sad study to assess safety, tolerability, pk, and pd of tu7710 in warfarin treated healthy male participants.

the 40 subjects will be divided into 5 cohorts, and the subjects assigned to each cohort will be randomly assigned with 6 persons receiving tu7710 and 2 persons receiving a placebo for tu7710. each cohort will proceed in sequence and the next cohort study will be decided by the safety monitoring committee (smc) . subjects will be participated in the study after warfarin anti-coagulation to maintain the inr between 2.00 and 3.00 as a preventive measure for potential thrombosis prior to the ip administration.

Eligibility criteria:
inclusion criteria: * age ≥19 and ≤45 * bmi of ≥18.0 kg/m2 and ≤30.0 kg/m2 * body weight of ≥55.0 kg and ≤90.0 kg * provide informed consent and willing to comply with study requirements. exclusion criteria: * history or at risk of developing diseases related to venous thromboembolic events or has family history of such disease * history of major bleeding/traumatic event or major surgery within 6 month * history of any other clinically relevant coagulation disorder (such as gastrointestinal bleeding, hemorrhoid hemorrhage) * abnormal coagulation related laboratory abnormal test results, including protein c, protein s, pt, aptt * history or current symptoms of gastrointestinal, liver, or renal disease that may affect the pharmacokinetics of the ip * history of or are currently with hepatitis b or c (active or carrier state) or human immunodeficiency virus (hiv) or syphilis infection. * currently smoking or have smoked within 1 month before ip or positive cotinine results * history of alcohol abuse or positive alcohol breath test * excessive caffeine intake within 7 days before ip * inr results not between 2.0\~3.0 range after warfarin treatment * history of hypersensitivity to medicinal product similar to tu7710 active ingredient or excipient * laboratory abnormal test results, such as qtcf \ 450msec (or family history of long qt syndrome), ldl \>190mg/dl , total cholesterol \>300mg/dl, triglycerides \> 350mg/dl, alt \>1.5\*uln, ast \>1.5\*uln, bilirubin \>1.5\*uln * abnormal vital sign sbp \>140mmhg, dbp \ 85bpm * any medical history that may increase the risk or affect the evaluation of study objectives by participating in this study at the discretion of the investigator. (e.g., neurology or psychiatric history)
contrast-enhanced ultrasound in predicting treatment response in patients with kidney cancer undergoing cryosurgery

Conditions: Renal Cell Carcinoma

Summary: this pilot clinical trial compares the imaging results of contrast-enhanced ultrasound to contrast-enhanced magnetic resonance imaging (mri) or computed tomography (ct), the current clinical standard, in predicting treatment response in patients with kidney cancer undergoing cryosurgery (a procedure in which an extremely cold liquid or an instrument called a cryoprobe is used to freeze and destroy abnormal tissue). using contrast-enhanced ultrasound that does not involve a dye may help patients avoid side effects from a dye that is usually used in mri or ct and may help doctors measure blood flow and determine whether the cryosurgery procedure treated the kidney tumor.

primary objectives: i. evaluate if contrast-enhanced ultrasound can be used to successfully evaluate the cryoablation (cryosurgery) of renal cell carcinoma. secondary objectives: i. establish whether contrast-enhanced ultrasound provides a reliable tool for the characterization of renal masses prior to cryoablation. tertiary objectives: i. compare harmonic imaging (the current industry standard for contrast imaging) with subharmonic imaging (a novel, improved contrast imaging technique) in the two aims listed above. outline: patients receive perflutren protein-type a microspheres intravenously (iv) and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during mri or ct follow up.

Eligibility criteria:
inclusion criteria: * be scheduled for a percutaneous cryoablation of a renal mass * be medically stable * if a female of child-bearing potential, must have a negative pregnancy test * have signed informed consent to participate in the study exclusion criteria: * females who are pregnant or nursing * patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable; for example: * patients on life support or in a critical care unit * patients with unstable occlusive disease (eg, crescendo angina) * patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia * patients with uncontrolled congestive heart failure (new york heart association \[nyha\] class iv) * patients with recent cerebral hemorrhage * patients with known sensitivities to albumin, blood, or blood products * patients who have undergone surgery within 24 hours prior to the study sonographic examination * patients with known hypersensitivity to perflutren * patients who have received any contrast medium (x-ray, mri, ct, or ultrasound \[us\]) in the 24 hours prior to the research us exam * patients with cardiac shunts * patients with congenital heart defects * patients with severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli * patients with respiratory distress syndrome * patients with renal insufficiency such that they can not get intravenous contrast as part of screening or follow-up
dislocated stable distal both-bone forearm fractures in children

Conditions: Fracture; Forearm; Distal; Child; Treatment

Summary: we create a randomized clinical trial between treatment with and without kirschner wire fixation of a stable dislocated distal both-bone forearm fracture.

children who arrive at the emergency unit with a dislocated both-bone distal forearm fracture will be asked to join the trial. after informed consent, a randomization between 2 kinds of treatment will be done: k-wire fixation or no k-wire fixation of the fracture after a stable reposition. outpatient clinic visits till a follow-up of 6 months. during these visits we will investigate: the number of re-dislocations, re-operations, consolidation and dislocation on x-ray, function of both arms, complains in daily living and complications.

Eligibility criteria:
inclusion criteria: * both-bone forearm fracture * distal * dislocated * stable after reposition * age \< 16 years exclusion criteria: * fracture older than 1 week * no informed consent * refracture * open fracture (gustillo 2 and 3) * both fractures of type torus

Keywords: fracture forearm distal child treatment
effect of bilirubin on prognosis in heart failure with preserved ejection fraction

Conditions: Heart Failure With Preserved Ejection Fraction; Prognathism

Summary: factors influencing the prognosis of patients with heart failure with preserved ejection fraction (hfpef) have been extensively studied. previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. however, the relationship between direct bilirubin and prognosis in patients with hfpef is unclear.

patients with heart failure with preserved ejection fraction account for approximately 50% of all heart failure patients, have approximately 1.4 hospitalisations per year and an annual mortality rate of approximately 15%. till now, there have no definitively proven therapies that can reduce their morbidity and mortality, hfpef patients have a poor prognosis. the current study found that the prognosis of patients with hfpef may be related to the heterogeneity of the disease, its various phenotypes and multifactorial pathophysiology, which has not been fully elucidated. the current study found that bilirubin is a risk factor for adverse outcomes of various hfpef-related complications, but the relationship between direct bilirubin and prognosis of hfpef has not been reported. therefore the investigators speculate that direct bilirubin is a predictor of prognosis of hfpef patients.

Eligibility criteria:
inclusion criteria: * adult aged ≥18 years old； * diagnosed with hfpef. diagnostic criteria including: 1. left ventricular ejection fraction ≥ 50%; 2. with the symptoms and/or signs of heart failure; 3. patients in sinus rhythm：bnp≥35pg/ml and/or nt-probnp≥125pg/ml；patients with atrial fibrillation：bnp≥105pg/ml and/or nt-probnp≥365pg/ml. exclusion criteria: * lvef less than 49% at any time

Keywords: heart failure with preserved ejection fraction bilirubin prognosis
ultrasonographic diameter of optic nerve sheath in fluid assessment in severe preeclamptic patients

Conditions: Severe Pre-eclampsia

Summary: changes in the optic nerve sheath diameter detected by ultrasound are considered an important manifestation of increased intracranial pressure . the normal optic nerve sheath diameter measures up to 5.0 mm and an average optic nerve sheath diameter more than 5 mm is considered abnormal and elevated intracranial pressure should be suspected.cerebral edema have been demonstrated in 71% to 100% of magnetic resonance imaging in preeclamptic patients and an increase in optic nerve sheath diameter has been described in preeclamptic females compared to healthy pregnant females therefore, increased optic nerve sheath diameter can indirectly reflect the state of intracranial edema that could be a part of generalized edema of preeclampsia and it could be a possible marker of generalized tissue edema and fluid overload in these patients.


Eligibility criteria:
inclusion criteria: * systolic blood pressure of 160mm hg or higher, or diastolic blood pressure of 110mm hg or higher on 2 occasions at least 6 hours apart on bed rest. * proteinuria ≥5g in a 24 hour urine specimen or ≥3+ on 2 random urine samples collected at least 4 hours apart. * patient acceptance * accepted mental state of the patients exclusion criteria: * patient refusal to participate in the study * chronic kidney disease * chronic pulmonary disease * chronic cardiac disease * chronic hypertension * previous ocular operation and diseases
sleep plus eating routines for weight loss

Conditions: Overweight and Obesity

Summary: the present study will test the effectiveness of two different approaches for preparing overweight/obese individuals for weight loss: 1)providing important information about weight control, including dispelling common myths; or 2) developing a consistent sleep and eating routine to prepare for the challenges of a weight control intervention.


Eligibility criteria:
inclusion criteria: * age 21 to 65 * bmi 25 to 45 * sleep 7 hours or less most nights exclusion criteria: * use of medications affecting sleep * sleep apnea * shift work

Keywords: weight loss
observational description of compliance for the daily ventavis use via the insight program in class iii pulmonary arterial hypertension patients

Conditions: Pulmonary Arterial Hypertension

Summary: this prospective, non-interventional, multi-center study documents observational data on subjects under routine treatment of pulmonary arterial hypertension, functional class iii with inhaled iloprost administered with i-neb aad (adaptive aerosol delivery) device. the observation period for each subject covers a one year treatment period with inhaled ventavis. for each subject, the investigator or a delegate collects data as defined in the case report form at an initial visit, routine follow-up visit at 6 months and final visit at 12 months.


Eligibility criteria:
inclusion criteria: * male or female subjects aged ≥18 years * newly treated with ventavis or treated with ventavis for less than 6 months, with i neb aad device for the application, as described in the smpc (summary of product characteristics), complemented by the insight * with pulmonary arterial hypertension, group i of the dana point pulmonary hypertension classification. * who (world health organization) /nyha (new york heart association) functional class iii * able and willing to give written informed consent for participation in the study exclusion criteria: key contra indications: * hypersensitivity to the active substance or to any of the excipients. * conditions where the effects of ventavis on platelets might increase the risk of haemorrhage (e.g. active peptic ulcers, trauma, intracranial haemorrhage). * severe coronary heart disease or unstable angina; * myocardial infarction within the last six months; * decompensated cardiac failure if not under close medical supervision; * severe arrhythmias; * cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months. * pulmonary hypertension due to venous occlusive disease. * congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension

Keywords: iloprost compliance
effects of massage therapy and facial pnf in early bell's palsy

Conditions: Bell Palsy

Summary: effects of massage therapy and facial pnf in early bell's palsy

it is an interventional study in which investigator will give massage therapy to one group of patients and facial pnf techniques to other group to evaluate the efficacy of these intervention on bell's palsy pateints

Eligibility criteria:
inclusion criteria: * both males and females with age between 20 to 50 years * all patients diagnosed with bell's palsy * non traumatic onset * acute onset 1 to 3 weeks * either right or left side exclusion criteria: * subject who have other neurological disorder * subjects who have impaired cognition * complete paralysis of face * open wound on face